Caribou Biosciences Inc. share price logo

Caribou Biosciences Inc.

NASDAQ: CRBU

$1.61

+0.04

(+2.55%)

as on

Caribou Biosciences Inc. Stock Performance

as on August 6, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $1.59
    $1.66
    downward going graph

    1.24%

    Downside

    3.11%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $1.38
    $3.54
    downward going graph

    14.29%

    Downside

    119.57%

    Upside

    downward going graph

Caribou Biosciences Inc. share price movements today

Previous Close
$1.57
Open
$1.59
Volume
1.3M
Day's Low - High
$1.59 - $1.66
52 Week Low - High
$1.38 - $3.54

Caribou Biosciences Inc. Historical Returns

1 Month Return
-12.02 %
3 Month Return
-17.44 %
1 Year Return
-14.36 %
3 Year Return
-76.04 %
5 Year Return
-92.81 %

Caribou Biosciences Inc. Stock Fundamentals & Key Indicators

Check Caribou Biosciences Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$155.7M

EPS (TTM)

-1.2467

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-114.2M

Revenue (TTM)

11.2M

Profit Margin

0.00%

Return On Equity TTM

-83.46%

Caribou Biosciences Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Caribou Biosciences Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$155.7M-92.81%NA0.00%NA
BUY$41.1B605.15%NA0.00%NA
BUY$121.3B141.61%27.9335.00%NA
BUY$78.3B25.82%18.827.87%0.48%

Stock Returns calculator for Caribou Biosciences Inc. Stock including INR - Dollar returns

The Caribou Biosciences Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Caribou Biosciences Inc. investment value today

Current value as on today

₹92,747

Returns

-₹7,253

(-7.25%)

Returns from Caribou Biosciences Inc. Stock

-₹14,362 (-14.36%)

Dollar Impact

₹7,109 (+7.11%)

Analyst Recommendation on Caribou Biosciences Inc. Stock

Based on 15 analysts

BUY

86.67%

Buy

13.33%

Hold

0.00%

Sell

Based on 15 analysts, 86.67% of analysts recommend a 'BUY' rating for Caribou Biosciences Inc.. Average target price of $12

Caribou Biosciences Inc. Share Price Target

Get share price movements and forecasts by analysts on Caribou Biosciences Inc..

What analysts predicted

86.58%UPSIDE

Target Price

$12

Current Price

$1.61

Analyzed by

15 Analysts

Target

$12.00

Caribou Biosciences Inc. target price $12, a slight upside of 86.58% compared to current price of $1.61. According to 15 analysts rating.

Indian Investors' Interest in Caribou Biosciences Inc. Stock

Search interest for Caribou Biosciences Inc. Stock has decreased by -25% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-25% versus previous 30 day period

Caribou Biosciences Inc. Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
3
2
3
2
2
2
2
2
3
2
Gross Profit
1
1
2
-27
-27
0
1
-20
3
1
Operating Income
-37
-46
-43
-38
-38
-42
-47
-29
-28
-26
EBITDA
-33
-40
-36
-33
-37
-38
-34
-26
-26
-24
Interest Expense
3
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
1
1
1
1
0
0
0
Income Before Tax
-34
-41
-37
-34
-35
-39
-54
-27
-27
-25
Income Tax Expense
0
0
-
-
0
-
-
-
0
-
Net Income
-34
-41
-37
-34
-35
-39
-54
-27
-26
-25
Net Profit Margin
-969.79%
-1697.57%
-1088.25%
-1713.64%
-1708.71%
-1699.58%
-2028.42%
-1253.32%
-672.11%
-1046.52%

Caribou Biosciences Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
5
12
9
13
34
9
11
Gross Profit
5
-22
8
10
30
6
7
Operating Income
-34
-36
-66
-106
-116
-166
-136
EBITDA
-30
-35
-65
-95
-98
-145
-145
Interest Expense
0
0
0
8
-
-
-
Depreciation
0
0
0
1
3
3
3
Income Before Tax
-30
-36
-66
-99
-101
-149
-148
Income Tax Expense
-7
-1
0
0
0
0
0
Net Income
-23
-34
-66
-99
-102
-149
-148
Net Profit Margin
-404.82%
-277.55%
-697.26%
-717.79%
-296.05%
-1491.95%
-1327.40%

Caribou Biosciences Inc. Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-41
-37
-34
-35
-39
-54
-27
-26
-25
Operating Cash Flow
-37
-32
-32
-35
-36
-28
-25
-20
-26
Investing Cash Flow
22
21
26
15
49
24
10
17
23
Financing Cash Flow
12
0
0
3
0
0
0
4
2
Change in Cash
-1
-11
-5
-15
13
-4
-14
1
0

Caribou Biosciences Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-34
-66
-99
-102
-149
-148
Operating Cash Flow
-33
-32
-90
-93
-138
-110
Investing Cash Flow
6
-176
-93
-68
86
102
Financing Cash Flow
1
433
2
154
16
4
Change in Cash
-25
224
-182
-7
-34
-3

Global Institutional Holdings in Caribou Biosciences Inc.

Funds
Holdings
Dimensional Fund Advisors, Inc.
0.68%
Maverick Capital Ltd
0.66%
AQR Capital Management LLC
0.69%
Charles Schwab Investment Management Inc
0.56%
CAMBRIDGE Invest RESEARCH ADVISORS, INC.
0.59%

Insights on Caribou Biosciences Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 4 quarters, -54.09M → -25.08M (in $), with an average increase of 35.3% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Revolution Medicines, Inc. Common Stock has given 438.0% return, outperforming this stock by 452.4%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 532.2% return, outperforming this stock by 608.2%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 3.94M → 2.39M (in $), with an average decrease of 39.2% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, CRBU stock has moved down by -12.0%

About Caribou Biosciences Inc.

Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
OrganisationCaribou Biosciences Inc.
Headquarters2929 7th Street, Berkeley, CA, United States, 94710
IndustryBiotechnology
CEODr. Rachel E. Haurwitz Ph.D.
E-voting on sharesClick here to vote

Key Management of Caribou Biosciences Inc.

Name

Title

Dr. Rachel E. Haurwitz Ph.D.

Co-Founder, CEO, President & Director

Dr. Jennifer A. Doudna Ph.D.

Co-founder & Member of Scientific Advisory Board

Mr. Ryan Fischesser

Interim Principal Accounting Officer & Controller

Mr. Timothy P. Kelly M.B.A.

Chief Technology Officer

Ms. Reigin Zawadzki

Chief People Officer

Mr. Sriram Ryali M.B.A.

Chief Financial Officer

Ms. Barbara G. McClung Esq., J.D.

Chief Legal Officer & Corporate Secretary

Ms. Ruhi A. Khan M.B.A.

Chief Business Officer

Dr. Tina Albertson M.D., Ph.D.

Chief Medical Officer

FAQs

What is Caribou Biosciences Inc. share price today?

Caribou Biosciences Inc. share price today is $1.61 as on at the close of the market. Caribou Biosciences Inc. share today touched a day high of $1.66 and a low of $1.59.

What is the 52 week high and 52 week low for Caribou Biosciences Inc. share?

Caribou Biosciences Inc. share touched a 52 week high of $3.54 on and a 52 week low of $1.38 on . Caribou Biosciences Inc. stock price today i.e. is closed at $1.61,which is 54.46% down from its 52 week high and 16.67% up from its 52 week low.

What is Caribou Biosciences Inc.'s market capitalisation today?

Caribou Biosciences Inc. market capitalisation is $0.00T as on .

How to invest in Caribou Biosciences Inc. Stock (CRBU) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Caribou Biosciences Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Caribou Biosciences Inc. Shares that will get you 0.9317 shares as per Caribou Biosciences Inc. share price of $1.61 per share as on August 6, 2026 at 8:46 am IST.

What is the minimum amount required to buy Caribou Biosciences Inc. Stock (CRBU) from India?

Indian investors can start investing in Caribou Biosciences Inc. (CRBU) shares with as little as ₹95.12 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹951.20 in Caribou Biosciences Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Caribou Biosciences Inc. share’s latest price of $1.61 as on August 6, 2026 at 8:46 am IST, you will get 6.2112 shares of Caribou Biosciences Inc.. Learn more about fractional shares .

What are the returns that Caribou Biosciences Inc. has given to Indian investors in the last 5 years?

Caribou Biosciences Inc. stock has given -92.81% share price returns and 28.66% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?